Angany’s choice to confront peanut allergy early on may seem evident. Afterall, not only is it one of the most common food allergies affecting children but it is also one…
Read More
News
QUEBEC CITY, QC CANADA, Val-de-Reuil, Normandy, FRANCE and AUSTIN, TX, March 24th, 2021. Dr Louis-Philippe Vézina CEO of Angany, and Mr. Bill Brydges, CEO of Phylloceuticals announce today that the…
Quebec City, QC, Canada and Val-de-Reuil, Normandy, France, March 10th, 2021 Dr Louis-Philippe Vézina Dr Véronique Gomord (respectively CEO and CSO of Angany), and Pr. Rogier W. Sanders and Dr…
For more information, see the article by the Santé Publique.
ANGANY CEO Dr. Louis-Philippe Vézina is very pleased to announce the collaboration of world-renowned Pr. Durham and Pr. Shamji, authorities in the field of allergy, to the activities of its…
Mr. St-Gelais is a director and business manager with an academic background in medicine and finance. A CFA charterholder, Mr. St-Gelais carries over twenty years of management experience mainly in…
ANGANY CEO Louis-Philippe Vézina is pleased to announce the nomination of Pr. Ronald van Ree PhD, as chairperson of ANGANY’s Scientific Advisory Board. Pr. Van Ree heads the Laboratory for…
Lévis, QC. – Built by Mecart Inc. of St-Augustin-de-Desmaures, QC during the challenging context of a pandemic, this production and analytic suite greatly adds to ANGANY’s operational capabilities and will…
Dr. Carrier brings over 20 years of management experience in the pharmaceutical industry with a history of success in developing, submitting and approving multiple drug applications in Canada, United States…
ANGANY has contracted the installation of a manufacturing pilot unit in clean rooms. This will provide a capacity to manufacture clinical batches in GMP conditions for Phase I and Phase…